Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-12-19

FDA Approved: FETZIMA — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for FETZIMA (levomilnacipran hydrochloride) submitted by Allergan, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FETZIMA (levomilnacipran hydrochloride)

Snippet

SUPPL AP for FETZIMA (LEVOMILNACIPRAN HYDROCHLORIDE)